Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that CEO David Stamler, M.D. will deliver a corporate update at the Bell Potter Healthcare Virtual Conference.

US presentation: Tuesday, 18 November 2025 at 6:30 p.m. PT / 9:30 p.m. ET. Australia presentation: Wednesday, 19 November 2025 at 1:30 p.m. AEDT (Sydney/Melbourne). Current and interested shareholders can register to view the webcast via the conference registration link.

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies. 

Presentation details

AUSTRALIA PARTICIPANTS:
Date:	Wednesday, 19 November 2025
Time:	1:30 p.m. AEDT (Sydney/Melbourne)

UNITED STATES PARTICIPANTS:
Date:	Tuesday, 18 November 2025
Time:	6:30 p.m. Pacific Time
	9:30 p.m. Eastern Time

Current and interested shareholders can register for the webcast here: Bell Potter | Healthcare 2025 (EXT)

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386

Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company’s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

When will Alterity Therapeutics (ATHE) present at the Bell Potter Healthcare conference?

Alterity will present on Tuesday, 18 November 2025 (US times) and Wednesday, 19 November 2025 (Australia AEDT).

What time is the Alterity (ATHE) webcast for US and Australia viewers?

US viewers: 6:30 p.m. PT / 9:30 p.m. ET on Nov 18, 2025. Australia viewers: 1:30 p.m. AEDT on Nov 19, 2025.

How can investors watch the Alterity (ATHE) corporate update webcast?

Investors can register and watch the webcast via the Bell Potter Healthcare 2025 conference registration link provided by the company.

Who will present Alterity's corporate update at the Bell Potter conference?

The presentation will be delivered by David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics.

Will Alterity (ATHE) provide financial guidance during the Bell Potter presentation?

The announcement states a corporate update will be delivered; it does not specify any financial guidance or detailed disclosures.